<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">98366</article-id>
<article-id pub-id-type="doi">10.7554/eLife.98366</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98366.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Computational and Systems Biology</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Kim</surname>
<given-names>Nayoung</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Park</surname>
<given-names>Sehhoon</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jo</surname>
<given-names>Areum</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eum</surname>
<given-names>Hye Hyeon</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Hong Kwan</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Kyungjong</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Jong Ho</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ku</surname>
<given-names>Bo Mi</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jung</surname>
<given-names>Hyun Ae</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Jong-Mu</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Se-Hoon</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahn</surname>
<given-names>Jin Seok</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jung-Il</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choi</surname>
<given-names>Jung Won</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeong</surname>
<given-names>Dasom</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Na</surname>
<given-names>Minsu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Huiram</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Jeong Yeon</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choi</surname>
<given-names>Jung Kyoon</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5123-0322</contrib-id>
<name>
<surname>Lee</surname>
<given-names>Hae-Ock</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a9">9</xref>
<email>haeocklee@catholic.ac.kr</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ahn</surname>
<given-names>Myung-Ju</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<email>silk.ahn@skku.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Microbiology, College of Medicine, The Catholic University of Korea</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a2"><label>2</label><institution>Department of Biomedicine and Health Sciences, Graduate School, The Catholic University of Korea</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a3"><label>3</label><institution>Division of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a4"><label>4</label><institution>Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a5"><label>5</label><institution>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a6"><label>6</label><institution>Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a7"><label>7</label><institution>Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
<aff id="a8"><label>8</label><institution>Department of Bio and Brain Engineering, KAIST</institution>, <city>Daejeon</city>, <country>Republic of Korea</country></aff>
<aff id="a9"><label>9</label><institution>Precision Medicine Research Center, College of Medicine, The Catholic University of Korea</institution>, <city>Seoul</city>, <country>Republic of Korea</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Wang</surname>
<given-names>Ching-Hao</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>GlaxoSmithKline</institution>
</institution-wrap>
<city>Cambridge</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Ng</surname>
<given-names>Tony</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>King's College London</institution>
</institution-wrap>
<city>London</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes><fn id="n1" fn-type="equal"><label>*</label><p>These authors contributed equally.</p></fn>
<fn id="n2" fn-type="conflict"><p>Conflicts of interest: The authors declare no potential conflicts of interest.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-06-11">
<day>11</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2024-10-15">
<day>15</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP98366</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-04-15">
<day>15</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-04-20">
<day>20</day>
<month>04</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.04.15.589544"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-06-11">
<day>11</day>
<month>06</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98366.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.98366.1.sa2">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.98366.1.sa1">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.98366.1.sa0">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.98366.1.sa3">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Kim et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Kim et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-98366-v2.pdf"/>
<abstract>
<title>Abstract</title><p>This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICI). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy. We conducted an analysis of single-cell transcriptomes from 33 lung cancer biopsy samples, with a particular focus on 14 core samples taken before the initiation of palliative ICI treatment. Our objective was to link tumor and immune cell profiles with patient responses to ICI. We discovered that ICI non-responders exhibited a higher presence of CD4+ regulatory T cells, resident memory T cells, and TH17 cells. This contrasts with the diverse activated CD8+ T cells found in responders. Furthermore, tumor cells in non-responders frequently showed heightened transcriptional activity in the NF-kB and STAT3 pathways, suggesting a potential inherent resistance to ICI therapy. Through the integration of immune cell profiles and tumor molecular signatures, we achieved an discriminative power (AUC) exceeding 95% in identifying patient responses to ICI treatment. These results underscore the crucial importance of the interplay between tumor and immune microenvironment, including within metastatic sites, in affecting the effectiveness of ICIs in NSCLC.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Immune checkpoint inhibitors</kwd>
<kwd>Responsiveness</kwd>
<kwd>Advanced lung cancer</kwd>
<kwd>Single-cell</kwd>
<kwd>Transcriptome</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Result section updated to provide explanations of updated figures
Discussion section updated to discuss specific cell populations and pathways
Table 2 added as a multivariate survival analysis for prognostic evaluation
Figure 2c updated to provide more conventional marker genes for TRM
Figure 2e updated to provide relative clone sizes
Supplemental files updated
</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Treatment landscape in cancer has rapidly evolved with the introduction of immune checkpoint inhibitors (ICI). Among various immune checkpoints, antibody-targeting programmed cell death-1 (PD-1) and its ligand (PD-L1) have demonstrated clinical benefits over conventional systemic chemotherapy in patients with non-small cell lung cancer (NSCLC). They have been approved as either monotherapy in patients with high PD-L1 expression <sup><xref ref-type="bibr" rid="c1">1</xref></sup> or combined with cytotoxic chemotherapy regardless of PD-L1 expression <sup><xref ref-type="bibr" rid="c2">2</xref>,<xref ref-type="bibr" rid="c3">3</xref></sup>. Moreover, the clinical benefits were validated in unresectable stage III NSCLC as consolidation therapy after definitive chemoradiotherapy or early stage NSCLC (Ib-IIIA) as adjuvant therapy after curative surgery <sup><xref ref-type="bibr" rid="c4">4</xref></sup>.</p>
<p>There have been many efforts to elucidate the predictive biomarkers of PD-(L)1 inhibitors. The PD-L1 expression in tumor tissue evaluated via immunohistochemistry has been incorporated as a companion diagnostic biomarker from the early clinical trials, which enhanced the response rate up to 46% in patients with PD-L1 ≥50% and showed an overall survival rate of up to 26.3 months <sup><xref ref-type="bibr" rid="c5">5</xref></sup>. Other biomarkers, such as tumor mutation burden or gene expression profile, also demonstrated a positive predictive value <sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c7">7</xref></sup>. Recent large-scale meta-analysis of clinico-immunogenomics shows that both tumor- and T cell intrinsic factors exert a substantial impact on ICI response <sup><xref ref-type="bibr" rid="c8">8</xref></sup>, supporting the necessity of in-depth investigation of high-throughput profiles of tumor and microenvironment.</p>
<p>ICI treatment modifies systemic immune responses, which can be monitored by alterations in the proportion of specific immune cell populations. An increase in PD-1+Ki67+CD8+ T cells in peripheral blood after PD-1 inhibitor treatment is associated with better outcomes in patients with NSCLC <sup><xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c10">10</xref></sup>. This cell type has also been identified in tumor tissues prior to the ICI treatment, where it is linked to clinical outcomes, and shows impaired production of classical effector cytokines <sup><xref ref-type="bibr" rid="c11">11</xref></sup>. More specifically, PD-1 expression is upregulated upon antigen recognition <sup><xref ref-type="bibr" rid="c12">12</xref></sup>, indicating that certain T cells in the tumor microenvironment are actively engaged as tumor-specific T cells. Beyond CD8+ T cells, other immune cell types, such as myeloid-derived suppressor cells or regulatory T cells, which regulate tumor-specific T cell immunity may also influence therapeutic outcomes <sup><xref ref-type="bibr" rid="c13">13</xref>–<xref ref-type="bibr" rid="c15">15</xref></sup>. Overall, the multicellular regulation of the tumor-immune microenvironment emphasizes the importance of profiling systemic tumor and immune cells at single cell resolution to investigate factors associated with responses to ICI treatment.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Variability and features of the lung cancer samples</title>
<p>We conducted scRNA-seq on 33 lung cancer samples from 26 patients treated with immune checkpoint inhibitors (ICI) between August 2017 and December 2019 to understand how cellular dynamics in lung cancer affect treatment sensitivity to PD-(L)1 inhibitors, used alone or in combination (<xref rid="fig1" ref-type="fig">Fig. 1a</xref> and Table S1). Immune checkpoint therapy provides clinical benefit in advanced metastatic NSCLC across different treatment lines <sup><xref ref-type="bibr" rid="c16">16</xref></sup>. Notably, our samples have been collected from various tissue sites. In the scRNA-seq analysis, all specimens were used for the cell type profiling in an unbiased manner. For the evaluation of clinical outcomes, only refined 14 core samples from 11 patients were used to minimize sample specific variations. Exclusion criteria from the core group encompass samples with treatment applied as adjuvant therapy, acquired after ICI treatment, no tumor content, non-evaluable for the clinical response, or histology other than non-small cell lung cancer such as nuclear protein in testis (NUT) and small cell lung cancer (SCLC) (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="fig1" ref-type="fig">Fig. 1a</xref>). Of the 11 core patients, 8 had adenocarcinoma (ADC) and 3 had squamous cell carcinoma (SQ). Clinical outcomes of ICI were partial response (PR) in four patients, stable disease (SD) in two patients, and progressive disease (PD) in five patients. Patients were classified as responders (PR) and non-responders (SD and PD) according to ICI response.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Cell lineage identification of 96,505 single cells from 26 patients with lung cancer treated with ICI.</title>
<p><bold>a,</bold> Workflow of sample collection and single-cell analysis of lung cancer patients treated with ICI. <bold>b,</bold> UMAP plot of 96,505 single cells from 33 samples acquired from 26 advanced lung cancer patients, colored by clusters. AMB cells, Ambiguous cells. <bold>c,</bold> Dot plot of mean expression of canonical marker genes for cell lineages. <bold>d,</bold> Proportions of the cell lineages in NSCLC tissue from core patients shown by individual samples aligned with clinical data. Labels for origins indicate LN, Metastatic lymph node; Lung, Tumor lung; PE, Malignant pleural effusion; Liver, Metastatic liver. <bold>e,</bold> Box plot of the percentage of cell lineages in responder and non-responder groups. Label represents p-value calculated via two-tailed Student’s t-test. Each box represents the median and the interquartile range (IQR, the range between the 25th and 75th percentile), whiskers indicate the 1.5 times of IQR.</p></caption>
<graphic xlink:href="589544v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Clinical overview of NSCLC patients treated with ICI.</title></caption>
<graphic xlink:href="589544v2_tbl1.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
<p>Due to the diversity of sample collection sites, our data may be influenced by varied immune cell composition at different sample collection sites. Therefore, we analyzed immune and stromal cell subsets across early-stage (tLung) and late-stage (tL/B) lung tumors, and metastatic lymph nodes (mLN), comparing them to normal lung (nLung) and lymph node (nLN) tissues. This analysis was conducted on public scRNA-seq data from 43 samples from 33 lung adenocarcinoma (LUAD) patients <sup><xref ref-type="bibr" rid="c17">17</xref></sup> (Fig. S1a-c). Although there were differences in tissue-specific resident populations, we found that the immune cell profiles, especially T/NK cells of mLN were similar to those of primary tumor tissues (Fig. S1d-g).</p>
</sec>
<sec id="s2b">
<title>Classification of immune cell subset in lung cancer</title>
<p>Global cell-type profiling (<xref rid="fig1" ref-type="fig">Fig. 1b,c</xref> and Table S2) illustrates the cellular composition of each sample as epithelial/tumor cells, fibroblasts, endothelial cells, T/natural killer (NK) cells, B/plasma cells, myeloid immune cells, and mast cells. Individual samples show variations in epithelial/tumor content as well as in immune cell composition (<xref rid="fig1" ref-type="fig">Fig. 1d,e</xref>). For further analysis of immune cell subtypes, we applied sequential subclustering on global immune cell clusters. As scRNA-seq shows limited performance in separating CD4+ and CD8+ T cell subsets, antibody-derived tag (ADT) information <sup><xref ref-type="bibr" rid="c18">18</xref></sup> was used to complement the transcriptome data and to predict CD4+ T cells, CD8+ T cells, and NK cells (<xref rid="fig2" ref-type="fig">Fig. 2a</xref>). Finally, fourteen CD4+ and fourteen CD8+ T cell subclusters were identified excluding &lt;5% ambiguous cells (<xref rid="fig2" ref-type="fig">Fig. 2b,c</xref> and Table S2). In the CD4+ T cell compartment, naïve-like T cells (TN, CD4_cluster0) and central memory T cells (TCM, CD4_cluster1) expressing <italic>SELL, TCF7, LEF1,</italic> and <italic>CCR7</italic> genes or tissue-resident memory T cells (TRM, CD4_clusters3, 5, 6) expressing <italic>NR4A1, MYADM,</italic> and <italic>PTGER4</italic> genes were abundant in most samples. Regulatory T cells (Treg, CD4_cluster2) with <italic>FOXP3, CTLA4, ICOS,</italic> and <italic>BATF</italic> expression were also abundant, which has been demonstrated as tumor-specific alterations in the tissue microenvironment <sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c19">19</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>. In the CD8+ T cell compartment, effector memory T cells (TEM), effector T cells (TEFF), effector memory CD45RA positive cells (TEMRA) (CD8_clusters0, 2, 3, 8) expressing <italic>PRF1</italic> and <italic>IFNG</italic> were dominant over TN/TCM (CD8_clusters4, 5) types. Exhausted T cells (TEX, CD8_clusters1, 12) expressed multiple checkpoint genes (<italic>HAVCR2</italic> and <italic>PDCD1</italic>) along with high levels of <italic>PRF1</italic>, <italic>IFNG</italic>, <italic>CXCR3,</italic> and <italic>CXCL13</italic>. Co-expression of cytotoxic effectors and checkpoint molecules in TEX clusters indicates that cluster populations may retain functional capacity as cytotoxic effector T cells <sup><xref ref-type="bibr" rid="c21">21</xref></sup>. Further, clonotype analysis of TCR supported the T cell subset classification demonstrating higher clonal expansion in the CD8+ T cell compartment than that in CD4+ T cells, with the highest levels within the TEX subclass (Fig. S2a-c).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Classification and characterization of CD4+ and CD8+ T cell subtypes.</title>
<p><bold>a,</bold> Prediction strategy to classify CD4+, CD8+ T, and NK cells by applying ADT data from lung cancer. <bold>b,</bold> UMAP plot of CD4+ and CD8+ T cells, colored by clusters. <bold>c,</bold> Dot plot of mean expression of selected CD4+ (left) and CD8+ (right) T cell marker genes in each cell cluster. <bold>d,</bold> Box plot of the percentage of CD4+ and CD8+ T cell types within total CD4+ plus CD8+ cells for sample groups representing responses to ICI. Label represents p-value calculated via two-tailed Student’s t-test. Each box represents the median and the IQR, whiskers indicate the 1.5 times of IQR. <bold>e,</bold> Association of T cell functional features with clonal expansion. Dot size depicts the relative clone size of each cell, which is divided by the total number of CD4+ and CD8+ T cells, respectively. Color indicates the cell lineage. <bold>f,</bold> Comparisons of proportional changes in cell subtypes along ICI responses within each immune cell lineage. The quantitative values shown on the axis represent the mean difference in % cell proportions between sample groups. Dot size and color represent -log (p-value) for responder vs. non-responder and non-PD vs. PD, respectively. The lower left quadrant shows cell types overrepresented in the poor responder groups, while the upper right quadrant indicates cell types overrepresented in the better responder groups. p-value, two-tailed Student’s t-test.</p></caption>
<graphic xlink:href="589544v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Natural killer cells can be subclassified as CD56bright, transitional, active, and mature types <sup><xref ref-type="bibr" rid="c22">22</xref></sup> (Fig. S3a,b and Table S2). Active NK cells expressed the highest level of <italic>PRF1</italic>, <italic>TNF,</italic> and <italic>IFNG,</italic> reflecting a cytotoxic effector function.</p>
<p>Compared to T cell clusters, fewer B/plasma cells were detected as follicular (B_clusters 0, 1, 2, 4, 6, 11), germinal center (B_cluster 10), and plasma/mucosa-associated lymphoid tissue (MALT) B cells (B_clusters 3, 7, 12) (Fig. S3a,b and Table S2). Plasma/MALT B cells manifested higher levels of clonal expansion of BCR than follicular B cells (Fig. S3c,d). Identical clonality of some follicular B and plasma cells suggests in situ maturation and differentiation of B cells to plasma cells in tumor tissues (Fig. S3c, clonotype 16).</p>
<p>Myeloid cells were composed of monocytes, dendritic cells, and a large number of macrophages (Fig. S3a,b and Table S2). CD14+CD16-classical monocytes (Myeloid_clusters1,6) were predominantly found over non-classical CD14<sup>lo</sup>CD16+ types (Myeloid_cluster15). Alveolar macrophages (Alveolar Mac, Myeloid_cluster0) expressed well-defined marker genes such as <italic>MARCO</italic>, <italic>FABP4</italic>, and <italic>MCEMP1</italic> along with anti-inflammatory genes such as <italic>CD163, APOE,</italic> and <italic>C1QA/B/C</italic>. Monocyte-derived macrophages represent heterogeneous populations with a similar gene expression profile to alveolar macrophages (Mo-Mac, Myeloid_clusters2, 3, 5, 9, 11, 13), with an elevated chemokine gene expression (CXCL10+ Mo-Mac, Myeloid_clusters4, 14, 16), or with active cell cycle progression (Proliferating Mac, Myeloid_cluster7). Dendritic cells were categorized as CD1c+ (Myeloid_cluster8, <italic>CD1C</italic> and <italic>ITGAX</italic>), activated (Myeloid_cluster17, <italic>CCR7</italic> and <italic>LAMP3</italic>), and CD141+ (Myeloid_cluster19, <italic>CLEC9A</italic> and <italic>XCR1</italic>) subclusters. Overall immune cell composition is comparable to those reported in previous studies <sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c19">19</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup>.</p>
</sec>
<sec id="s2c">
<title>Immune cell landscape fostering the ICI response</title>
<p>In global cell-type profiling (<xref rid="fig1" ref-type="fig">Fig. 1b,c</xref>), abundance in T, NK, or myeloid cell types shows no difference between responders and non-responders (<xref rid="fig1" ref-type="fig">Fig. 1d, e</xref>). Nonetheless, as specific differentiation features within the cell types may influence the response to ICI treatment, we compared the response groups using the proportion of subclusters within CD4+ T, CD8+ T, NK, B/plasma, and myeloid cells. After subclustering (<xref rid="fig2" ref-type="fig">Fig. 2b</xref> and Fig. S3a), three subsets of CD4+ T cells, i.e., Treg, TRM, and CD4+ T helper 17 (TH17), were significantly (p&lt;0.01) overrepresented in the non-responder group (<xref rid="fig2" ref-type="fig">Fig. 2d</xref>). In contrast, among CD8+ T cell populations, TEM subsets demonstrated a modest level of association with the patients who responded well against progressive disease (<xref rid="fig2" ref-type="fig">Fig. 2d, p</xref>=0.06). TCR clonotype analysis supported the cellular dynamics such that clonal expansion was more prominent in cytotoxic CD8+ T cells over CD4+ Tregs in the responder group (<xref rid="fig2" ref-type="fig">Fig. 2e</xref> and Fig. S2c). Overall landscape in each cell type (<xref rid="fig2" ref-type="fig">Fig. 2f</xref>) suggests that CD4+ Treg and TRM as well as follicular B cells may interfere with the ICI response, whereas CD8+ T cell activation (TEM, TEMRA/TEFF, and TEX), mature NK cells, and CXCL10+ Mo-Mac cells support the ICI response. The balance between separate immune cell types informs immune regulatory axes that may be targeted to favor the activation of tumor-reactive immunity.</p>
</sec>
<sec id="s2d">
<title>Systemic evaluation of the immune microenvironment associated with ICI response</title>
<p>Next, we evaluated the immune microenvironment as an entity by using all immune cells as a denominator in the subtype proportions. In this setting, we used diverse clinical group comparisons and identified the immune cell blocks separated by clinical outcomes (<xref rid="fig3" ref-type="fig">Fig. 3a</xref>). The immune cell blocks overrepresented in the non-responder groups consisted of CD4+ Treg, follicular B cells, and CD4+ TH17/TRM/ T helper 1 (TH1)-like cells. In the immune cell blocks of the responder groups, CD8+ TEM cells showed the strongest enrichment along with the other CD8+ TEX/TEMRA/TEFF/Mitochondria (MT) high cells as well as CXCL10+ Mo-Mac. Despite the immune footprints of the ICI responders, extensive variations among individual patients (<xref rid="fig3" ref-type="fig">Fig. 3b</xref>) hamper patient stratification solely based on the immune profiles.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Systemic evaluation of immune cell dynamics associated with response to ICI.</title>
<p><bold>a,</bold> Heat map with unsupervised hierarchical clustering (left) and depicting significance (right) of proportional changes in cell subtypes within total immune cells. Proportional changes were compared for multiple ICI response groups. Color represents the -log (p-value) determined using two-tailed Student’s t-test. <bold>b,</bold> Distribution map for each cell type across individual samples aligned with clinical data. Color represents <italic>Ro/e</italic> score calculated using the chi-square test.</p></caption>
<graphic xlink:href="589544v2_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2e">
<title>Tumor cell signatures associated with ICI response</title>
<p>We investigated the associations between genomic characteristics in tumor and ICI response. The constraints of mutation analysis with 10x chromium data complicated the direct correlation between tumor mutation burden and ICI outcome. Rather, we assessed copy number alterations (CNA) indirectly, via chromosomal gene expression patterns. These analyses revealed a moderate correlation between low levels of CNA, including both gain and loss of heterozygosity, and positive responses to ICI (Fig. S4). This finding is consistent with the result from previous genetic association studies <sup><xref ref-type="bibr" rid="c23">23</xref></sup>.</p>
<p>To assess gene expression characteristics of tumors influencing ICI response, we separated malignant tumor cell clusters from normal epithelial cell types (Fig. S5). Subsequent DEG analysis (<xref rid="fig4" ref-type="fig">Fig. 4a</xref> and Table S3) identified genes in poor response groups linked to the regulation of cell death, cell motility, and cell activation (Fig. S6 and Table S4). The DEGs were refined later by combinations of various tumor signatures separating responder and non-responder groups (Table S5).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Single-cell tumor signatures associated with response to ICI.</title>
<p><bold>a,</bold> Volcano plot of expression difference for responder vs. non-responder, PR vs. PD, and PR vs. SD in 12,975 malignant cells from 11 core patients. The log fold change indicates the difference in the mean expression level for each gene. The significance level was determined using two-tailed Wilcoxon Rank Sum test. <bold>b,</bold> Relative sum of loadings for all NMF factors contributed to malignant cells from 11 core patients across RECIST, tissue origins, and cancer subtypes, respectively. <bold>c,</bold> Selection of RECIST-enriched NMF programs. <bold>d,</bold> Enrichment of NMF programs for RECIST groups. Color represents the z-transformed odds ratio. <bold>e,</bold> Expression map of RECIST-specific scINSIGHT modules across individual samples aligned with clinical data. Color represents the z-transformed mean expression of genes contributing to each module. <bold>f,</bold> Enrichment of RECIST-specific gene modules for RECIST groups. Color represents the z-transformed odds ratio. <bold>g,</bold> Hierarchical clustering of pairwise similarities between tumor signatures. INT and UNION, intersection and union of DEGs for responder vs. non-responder, PR vs. PD, and PR vs. SD in <xref rid="fig4" ref-type="fig">Fig. 4a</xref>. <bold>h,</bold> Functional categories and <bold>i,</bold> transcription factors of the selected tumor signatures, analyzed by Metascape.</p></caption>
<graphic xlink:href="589544v2_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Next, to explore the existence of gene programs and modules influencing the ICI response, we applied factorization using non-negative matrix factorization (NMF) and scINSIGHT <sup><xref ref-type="bibr" rid="c24">24</xref></sup>. Among 30 factors from NMF across all malignant cells, we identified factors showing high loadings for a specific RECIST group as NMF programs p1∼4 (<xref rid="fig4" ref-type="fig">Fig. 4b, c</xref>). There were clear distinction among RECIST groups according to the gene expression levels associated with these NMF programs (<xref rid="fig4" ref-type="fig">Fig. 4d</xref> and Table S5). To identify gene modules consistent across different patients, we examined RECIST-specific modules though scINSIGHT analysis <sup><xref ref-type="bibr" rid="c24">24</xref></sup> (<xref rid="fig4" ref-type="fig">Fig. 4e</xref>). Unfortunately, we found that contributions to these gene modules varied significantly among patients. To mitigate this variability, we adjusted the RECIST-specific modules by combining genes from the original modules (Table S5). The refined gene modules showed a specific gene expression pattern for each RECIST group, similar to the NMF programs (<xref rid="fig4" ref-type="fig">Fig. 4f</xref>). Overall, both genes and their functional categories segregated depending on the selection techniques used (<xref rid="fig4" ref-type="fig">Fig. 4g, h</xref>). However, transcription factors governing the signatures derived from DEG, NMF, and scINSIGHT analyses consistently delineated between responders and non-responders (<xref rid="fig4" ref-type="fig">Fig. 4i</xref>). Responder-specific gene signatures showed associations with the transcription factors Regulatory Factor X Associated Ankyrin Containing Protein (RFXANK), Regulatory Factor X Associated Protein (RFXAP), and Regulatory Factor X5 (RFX5). This RFX protein complex has emerged as a positive biomarker for the immune response in diverse cancer types <sup><xref ref-type="bibr" rid="c25">25</xref></sup>. Non-responder-specific gene signatures were regulated by Activator Of Transcription 3 (STAT3) and Nuclear Factor Kappa B Subunit 1 (NFKB1), known to play roles in PD-L1 regulation and T cell activation in cancer <sup><xref ref-type="bibr" rid="c26">26</xref></sup>.</p>
<p>We also adopted principal component analysis (PCA) to isolate correlated gene signatures variably expressed in tumor cells (Fig. S7, and Table S4, S5). Among the top 10 PCs, negatively correlated genes in PC2, PC7, and PC8 distinguished the tumor cells in the poor response groups, whereas positively correlated genes in PC6 and PC9 were upregulated in the better response groups (Fig. S8a-c). Tumor cells from the PR group had low PC2.neg scores, suggesting low growth factor/type I interferon response signaling as a tumor cell-specific positive predictor of the ICI response. Conversely, high levels of growth factor/type I interferon response signaling in tumor cells may present intrinsic resistance to PD-(L)1 inhibitor alone or in combination. Type I interferon is known to drive anti-tumor effect directly or indirectly on tumor and surrounding immune cells, but also acts to counter the anti-tumor effect by inducing CD8+ T cell exhaustion and up-regulating immune-suppressive genes on tumor cells <sup><xref ref-type="bibr" rid="c27">27</xref></sup>. We assessed whether tumor cell signatures are applicable in association with ICI response in other tumors. They had a modest influence on the response to ICI treatment of melanoma (Fig. S8d) in bulk gene expression data <sup><xref ref-type="bibr" rid="c28">28</xref>,<xref ref-type="bibr" rid="c29">29</xref></sup>.</p>
<p>These tumor cell signatures were specifically linked to elucidating the ICI response, but did not demonstrate any prognostic value for LUAD or lung squamous cell carcinoma (LUSC) in the TCGA RNA sequencing data (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption><title>Multivariate overall survival analysis of tumor signature genes.</title></caption>
<graphic xlink:href="589544v2_tbl2.tif" mime-subtype="tiff" mimetype="image"/>
</table-wrap>
</sec>
<sec id="s2f">
<title>Combination of tumor signatures and immune cell dynamics classify ICI response</title>
<p>Immune cell dynamics or tumor signature alone has a limited capacity to profile the therapeutic outcome of PD-(L)1 inhibitor alone or in combination (<xref rid="fig5" ref-type="fig">Fig. 5a</xref>). Similar to the immune cell blocks and tumor signatures that were over-represented in the poor response group, each of CD4+ Treg, CD4+ TH17, PC7.neg, INT.down, and UNION.down was significantly associated with ICI response in univariate regression analysis (<xref rid="fig5" ref-type="fig">Fig. 5b</xref>). PC7.neg denotes genes negatively correlated with PC7, a principal component extracted from PCA that distinguishes tumor cells in poor response groups. INT.down and UNION.down represent the intersection and union of down-regulated genes in the responder group, respectively. The variation in ICI response was not affected by clinical variables of tissue origin, cancer subtype, pathological stage, and smoking status. When we performed a combined analysis of the top tumor-immune features to classify response, the discriminative power (AUC) was improved to over 95% (<xref rid="fig5" ref-type="fig">Fig. 5c</xref>). Overall, features of the non-responders, especially CD4+ Treg, B/Plasma cells, INT.down, and UNION.down, showed a higher estimate than those of responders. These non-responder features suggest heterogeneous mechanisms of resistance conferred by tumor and immune regulatory axes.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Combination of tumor signatures and immune index classifying the response to ICI.</title>
<p><bold>a,</bold> Heat map of relative contribution of tumor signatures and immune index across individual samples aligned with clinical data. Mean expression of each tumor signature and the percentage of each immune index are divided by the maximum value across samples. INT and UNION, intersection and union of DEGs for responder vs. non-responder, PR vs. PD, and PR vs. SD in <xref rid="fig4" ref-type="fig">Fig. 4a</xref>. <bold>b,</bold> Univariate regression analysis of immune and tumor signatures for ICI response, together with clinical variables. <bold>c,</bold> ROC analysis of combinatorial index to classify responder and non-responder. p-value, two-tailed Wilcoxon Rank Sum test. P-values adjusted with the Benjamini-Hochberg correction; UNION.down + B/Plasma, 0.22; INT.down + B/Plasma, 0.22; UNION.down + CD4+ Treg, 0.26; INT.down + UNION.down, 0.26; INT.down, 0.26; UNION.down, 0.26.</p></caption>
<graphic xlink:href="589544v2_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>ICI alone, or in combination with chemotherapy, are considered standard first-line therapy for patients with NSCLC. NSCLC may harbor large numbers of genetic perturbations due to genotoxic environmental exposure, which likely generate high mutation burden or neoantigens <sup><xref ref-type="bibr" rid="c30">30</xref></sup>. The neoantigen-directed T cell response is hampered by diverse immune suppressive mechanisms exerted by tumor cells and the immune regulatory network <sup><xref ref-type="bibr" rid="c31">31</xref></sup>. Current ICIs targeting PD-(L)1 aim one angle of many suppressive mechanisms, and identifying the features of non-responders will reveal additional regulatory angles to improve ICI response.</p>
<p>Immune regulatory network would determine the balance between activation and suppression of tumor-directed immunity. In previous studies, prediction of the response to ICI highlighted CD8+ cytotoxic effector T cells and CD4+ Tregs <sup><xref ref-type="bibr" rid="c32">32</xref></sup>. The involvement of effector CD8+ T cells is consistent in most studies regardless of the cellular origin (blood or tissues) or tumor type (melanoma, lung cancer) <sup><xref ref-type="bibr" rid="c33">33</xref></sup>. Their phenotypes slightly differ depending on the cellular resolution of the study. Our data provided the highest resolution cell types, and CD8+ TEM cells (<italic>GZMK</italic>, <italic>CXCR4</italic> expression) were overrepresented in the responders. By comparison, Tregs were underrepresented in the responder group. Previously, our group reported a contrasting result demonstrating an increase in Tregs in the posttreatment blood samples (not baseline) in the responder group <sup><xref ref-type="bibr" rid="c34">34</xref></sup>. This discrepancy can be explained by the differences in the measurements, sites, and timing of sampling, and the resolution of subpopulations. In mouse preclinical models, PD-L1 inhibitor treatment induces T cell expansion of all phenotypes including CD4+/CD8+ TEFF and Tregs <sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Thus, Treg expansion captured in the posttreatment blood samples may represent overall immune activation in human patients. Alternatively, heterogeneity of Tregs and complex effects of PD-(L)1 inhibition on this cell type may contribute to variable results in response prediction.</p>
<p>The identification of an abundance of CD4+ TRM cells as a negative predictor of ICI response is an unexpected finding, considering that higher frequencies of TRM cells in lung tumor tissues are generally associated with better clinical outcomes in NSCLC <sup><xref ref-type="bibr" rid="c36">36</xref></sup>. This is largely due to their role in sustaining high densities of tumor-infiltrating lymphocytes and promoting anti-tumor responses. Additionally, previous studies have demonstrated that TRM cell subsets coexpressing PD-1 and TIM-3 are relatively enriched in patients who respond to PD-1 inhibitors <sup><xref ref-type="bibr" rid="c37">37</xref></sup>. However, recent findings suggest that pre-existing TRM-like cells in lung cancer may promote immune evasion mechanisms, contributing to resistance to immune checkpoint blockade therapies <sup><xref ref-type="bibr" rid="c38">38</xref></sup>. These observations suggest that the roles of TRM subsets in tumor immunity are highly context-dependent.</p>
<p>Similarly, CD4+ TH17 cells, which were overrepresented in the non-responder groups, exhibit context-dependent roles in tumor immunity and may be associated with both unfavorable and favorable outcomes <sup><xref ref-type="bibr" rid="c39">39</xref>,<xref ref-type="bibr" rid="c40">40</xref></sup>. In exploring tumor cell signatures linked to ICI response, non-responder attributes were regulated by STAT3 and NFKB1. The STAT3 and NF-κB pathways are crucial for Th17 cell differentiation and T cell activation <sup><xref ref-type="bibr" rid="c41">41</xref>,<xref ref-type="bibr" rid="c42">42</xref></sup>. Notably, STAT3 activation in lung cancer orchestrates immunosuppressive characteristics by inhibiting T-cell mediated cytotoxicity <sup><xref ref-type="bibr" rid="c43">43</xref></sup>. The combined influence of the Th17/STAT3 axis and TRM cell activity in predicting ICI response underscores the complexity of these pathways and suggests that their roles in tumor immunity and therapy response warrants further investigation.</p>
<p>In search of tumor cell signatures associated with the response to ICI, we adopted two approaches, an individual gene level comparison between the responder and non-responder group and a feature extraction approach to decompose data using the NMF and PCA. Both approaches highlighted attributes of non-responders governed by key transcription factors, which play a significant role in immune response regulation. The ability to predict ICI response based on tumor signatures was as accurate as predictions based on immune cell behavior. Integrating data from both immune and tumor cells enhanced the discriminative power (AUC) for identifying responder, suggesting the presence of both interactive and distinct mechanisms of resistance.</p>
<p>Our study has limitations. Primarily, most samples were obtained from metastatic lymph nodes rather than original tumor tissues, potentially not reflecting the tumor microenvironment accurately. However, prior study <sup><xref ref-type="bibr" rid="c17">17</xref></sup> and Fig. S1 have shown that the immune microenvironment within metastatic lymph nodes closely resembles that of lung tumor tissues, rather than normal lymph nodes. On a positive note, our findings indicate that the immune landscape of metastatic lymph nodes can predict ICI response. Another challenge is the small sample size and the issue of gene expression drop-out, necessitating further studies with a larger patient cohort. Despite these limitations, our study stands out by employing high-throughput scRNA-seq to both tumor cells and immune microenvironment, offering a comprehensive analysis of the multicellular factors that affect ICI response in patients with advanced NSCLC.</p>
</sec>
<sec id="s4">
<title>Materials and methods</title>
<sec id="s4a">
<title>Human specimens</title>
<p>This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center (IRB no. 2010-04-039-052). Informed written consent was obtained from all patients enrolled in the study. The study participants included 26 patients diagnosed with lung cancer (Table S1). The study population (n=26) has been treated with the investigator’s choice either as a clinical trial (n=5) or as standard clinical practice (n=21). Regardless of the treatment selection, the specimens were prospectively collected based on the study protocol. A total of 33 samples were collected and immediately transferred on ice for tissue preparation. Metastatic lymph nodes, metastatic liver tissues, and lung/bronchus tumor tissues from patients with lung cancer were collected using endobronchial ultrasound bronchoscopy, neck lymph node ultrasound and biopsy, liver biopsy, and percutaneous transthoracic cutting needle biopsy. Tumors, normal lungs, normal lymph nodes, and normal brain tissues were obtained during resection surgery. Pleural fluid was collected from patients with malignant pleural effusion.</p>
</sec>
<sec id="s4b">
<title>Clinical outcomes</title>
<p>The clinical outcomes of ICI were evaluated based on the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 <sup><xref ref-type="bibr" rid="c44">44</xref></sup>. In this study, we described non-responders as patients with a stable or progressive disease. Responders were considered as patients with a partial response. None of the patients showed a complete response.</p>
</sec>
<sec id="s4c">
<title>Sample preparation</title>
<p>Single-cell isolation was performed differently depending on the samples. (1) Biopsy samples and normal lymph node tissues were chopped into 2-4 mm pieces and dissociated in an enzyme solution containing collagenase/hyaluronidase (STEMCELL Technologies, Vancouver, Canada) and DNase I, RNase-Free (lyophilized) (QIAGEN, Hilden, Germany) at 37°C for 1 h. Tissue pieces were re-mixed by gentle pipetting at 20-min intervals during incubation. (2) Tumor and normal lung tissue dissociation was performed using a tumor dissociation kit (Miltenyi Biotech, Germany) following the manufacturer’s instructions. Briefly, tissue was cut into 2–4 mm pieces and transferred to a C tube containing the enzyme mix (enzymes H, R, and A in RPMI1640 medium). The GentleMACS programs h_tumor_01, h_tumor_02, and h_tumor_02 were run with two 30-min incubations on a MACSmix tube rotator at 37°C. (3) Brain tissue was chopped into 2–4 mm pieces and incubated in an enzyme solution (collagenase (Gibco, Waltham, MA, USA), DNase I (Roche, Basel, Switzerland), and Dispase I (Gibco) in DMEM) at 37°C for 1 h. Tissue pieces were re-mixed by gentle pipetting at 15-min intervals during incubation. (4) Pleural fluids were transferred to a 50-ml tube, and the cells were spun down at 300g.</p>
<p>Each cell suspension was transferred to a new 50-ml (15-ml for biopsy samples) tube through a 70-µm strainer. The volume in the tube was readjusted to 50-ml (or 15-ml) with RPMI1640 medium, and spun down to remove the enzymes. The supernatant was aspirated, the cell pellet was resuspended in 4 ml of RPMI1640 medium, and dead cells were removed using Ficoll-Paque PLUS (GE Healthcare, Chicago, IL, USA) separation.</p>
<p>For samples subjected to multiplexing, dissociated cells were cryopreserved in CELLBANKER1 (Zenogen, Fukushima, Japan) and thawed for pooling.</p>
</sec>
<sec id="s4d">
<title>Single-cell RNA sequencing (scRNA-seq) and read processing</title>
<p>Single-cell suspensions were loaded into a Chromium system (10x Genomics, Pleasanton, CA, USA). Following the manufacturer’s instructions, 3’ scRNA-seq libraries for the 14 samples were generated using Chromium Single Cell 3′ v2 Reagent Kits. The 3’ library preparation for EBUS_119 used Chromium Single Cell 3′ v3 Reagent Kits. The 5’ scRNA-seq libraries for twelve individual and two pooled samples were generated using Chromium Single Cell 5′ v2 Reagent Kit. Libraries were then sequenced on an Illumina HiSeq 2500 for 3’ scRNA-seq and an Illumina NovaSeq 6000 for 5’ scRNA-seq. Sequencing reads were mapped to the GRCh38 human reference genome using Cell Ranger toolkit (v5.0.0).</p>
</sec>
<sec id="s4e">
<title>SNP genotyping array</title>
<p>Genomic DNA was extracted from the peripheral blood of six patients and subjected to sample multiplexing (DNeasy Blood &amp; Tissue Kit, QIAGEN). The 766,221 single nucleotide polymorphisms (SNPs) was genotyped using Illumina Global Screening Array MG v2, following the manufacturer’s instructions. Normalized signal intensity and genotype were processed using Illumina’s GenomeStudio v.2 software.</p>
</sec>
<sec id="s4f">
<title>Demultiplexing of pooled samples</title>
<p>The individuals in sample multiplexing were assigned by a software tool <italic>freemuxlet</italic>, which is an extension of <italic>demuxlet</italic> <sup><xref ref-type="bibr" rid="c45">45</xref></sup> (<ext-link ext-link-type="uri" xlink:href="https://github.com/statgen/popscle">https://github.com/statgen/popscle</ext-link>). First, the popscle tool <italic>dsc-pileup</italic> was run with the bam file generated by Cell Ranger toolkit and reference vcf file. The reference was assembled after a lift-over process with GRCh38 from 1000 Genomes Project phase 1 data and the variant allele frequency in East Asian &gt;0.01 were discarded. Next, <italic>freemuxlet</italic> was used to determine the sample identity with default parameters. The individuals were matched based on the similarity between freemuxlet-annotated genotypes and SNP array-detected genotypes.</p>
</sec>
<sec id="s4g">
<title>Acquisition of scRNA-seq data from lung adenocarcinoma (LUAD) patients</title>
<p>We obtained raw 3’ scRNA-seq from 43 specimens acquired from 33 LUAD patients including early-stage (tLung) and late-stage (tL/B) lung tumor tissues, metastatic lymph nodes (mLN), normal lung tissues (nLung) and lymph nodes (nLN) <sup><xref ref-type="bibr" rid="c17">17</xref></sup>. Sequencing reads were mapped to the GRCh38 human reference genome using Cell Ranger toolkit (v5.0.0).</p>
</sec>
<sec id="s4h">
<title>scRNA-seq data analysis</title>
<p>The raw gene-cell-barcode matrix from Cell Ranger pipeline was processed using Seurat v3.2.2 R package <sup><xref ref-type="bibr" rid="c46">46</xref></sup>. Cells were selected using two quality criteria: mitochondrial genes (&lt;20%) and gene count (&gt;200). Cell multiplets predicted by Scrublet <sup><xref ref-type="bibr" rid="c47">47</xref></sup> were filtered out. From the filtered cells, the unique molecular identifier (UMI) count matrix was log-normalized and scaled by z-transform while regressing out the effects of cell-cycle variations for subsequent analysis. For batch correction, we used Harmony v1.0 R package <sup><xref ref-type="bibr" rid="c48">48</xref></sup> interfacing with Seurat as the <italic>RunHarmony</italic> function. A total of 2,000 variably expressed genes were selected using <italic>FindVariableFeatures</italic> with a parameter selection.method=“vst”. A subset of principal components (PCs) was selected based on <italic>ElbowPlot</italic> function. Uniform Manifold Approximation and Projection (UMAP) for dimension reduction and cell clustering was performed using <italic>RunUMAP, FindNeighbors</italic>, and <italic>FindClusters</italic> functions with the selected PCs and resolutions [Advanced lung cancer patients (Total cells, 33 PCs and resolution=0.3; CD4+ T cells, 28 PCs and resolution=0.9; CD8+ T cells, 28 PCs and resolution=0.9; NK cells, 26 PCs and resolution=0.3; B/Plasma cells, 28 PCs and resolution=0.3; Myeloid cells, 30 PCs and resolution=1.2), LUAD patients (Total cells, 23 PCs and resolution=0.3; T/NK cells, 24 PCs and resolution=0.9)]. We applied the <italic>FindAllMarkers</italic> function to identify differentially expressed genes (DEGs) for each cell cluster. Significance was determined using Wilcoxon Rank Sum test. Genes were selected according to the following statistical thresholds; log fold change&gt;0.25, p-value&lt;0.01, adjusted p-value (bonferroni correction)&lt;0.01, and percentage of cells (pct)&gt;0.25. Cell identity was determined by comparing the expression of known marker genes and DEGs for each cluster.</p>
</sec>
<sec id="s4i">
<title>Principal component analysis (PCA) analysis using the proportion of cell lineages and T/NK cell subsets</title>
<p>PCA analysis was performed for the % proportion of cell lineages and T/NK cell subsets in individual LUAD samples using <italic>prcomp</italic> function of stats v3.6.3 R package. For total cells, the percentages of immune and stromal cells were calculated except for epithelial, cycling, and AMB (ambiguous) cells. For T/NK cells, unknown cells annotated as MT high and AMB cells were excluded.</p>
</sec>
<sec id="s4j">
<title>In silico classification of CD4+ T, CD8+ T, and NK cells</title>
<p>We characterized CD4+ T, CD8+ T, and NK cell populations by combined analysis of gene and protein expression using Cellular Indexing of Transcriptomes and Epitopes by Sequencing data from primary tumor and normal lungs. Among the cells in clusters annotated as T/NK cells, we identified CD3-expressing cells with CD3D or CD3E or CD3G &gt;0 at the RNA level. CD4 and CD8 positive cells were then identified with a cutoff at 55th percentile of antibody-derived tags (ADT) level. NK cells were identified based on the RNA expression level of NK cell markers (<italic>XCL1</italic>, <italic>NCAM1</italic>, <italic>KLRD1</italic>, and <italic>KLRF1</italic>) in CD3 negative cells. The gene expression matrix with cell identity of CD4 positive, CD8 positive, and NK was applied as reference data for supervised cell-type classification using <italic>getFeatureSpace</italic> and <italic>trainModel</italic> functions of scPred v1.9.0 R package <sup><xref ref-type="bibr" rid="c49">49</xref></sup>. Finally, we classified T/NK cells in <xref rid="fig1" ref-type="fig">Fig. 1b</xref> into CD4+ T, CD8+ T, and NK cells using scPred <italic>scPredict</italic> function.</p>
</sec>
<sec id="s4k">
<title>Analysis of TCR/BCR repertoires in CD4+ T, CD8+ T, and B/Plasma cells</title>
<p>The data derived from Cell Ranger pipeline for T cell receptor (TCR) and B cell receptor (BCR) sequencing data were processed using scRepertoire v1.2.0 R package <sup><xref ref-type="bibr" rid="c50">50</xref></sup> in R v4.1.1. We selected contigs that generated alpha-beta chain pairs for TCR and heavy-light chain pairs for BCR for subsequent analysis. We called clonotypes based on V(D)JC genes and CDR3 nucleotide sequence with the parameter clonecall=“gene+nt”. The set of clone types was classified by total frequency using the parameter cloneTypes defined as Single=1, Small=5, Medium=10, Large=20, and Hyperexpanded=Inf.</p>
</sec>
<sec id="s4l">
<title>Scoring of T cell functional features</title>
<p>Scores for T cell functional features were calculated as the mean expression of regulatory (<italic>ICOS</italic>, <italic>FOXP3</italic>, <italic>IKZF2</italic>, <italic>LAYN</italic>, <italic>TNFRSF18</italic>, <italic>CTLA4</italic>, <italic>IL21R</italic>, <italic>BATF</italic>, <italic>CCR8</italic>, <italic>IL2RA</italic>, and <italic>TNFRSF4</italic>) and cytotoxic (<italic>CX3CR1</italic>, <italic>PRF1</italic>, <italic>GZMA</italic>, <italic>GZMB</italic>, <italic>GZMH</italic>, <italic>GNLY</italic>, <italic>KLRG1</italic>, and <italic>NKG7</italic>) genes at the log-normalized level.</p>
</sec>
<sec id="s4m">
<title>Identification of malignant cells based on inferred copy number variation (CNV) from scRNA-seq data</title>
<p>Two computational tools, inferCNV v1.2.1 (<ext-link ext-link-type="uri" xlink:href="https://github.com/broadinstitute/inferCNV">https://github.com/broadinstitute/inferCNV</ext-link>) and CopyKAT v1.0.5 R packages <sup><xref ref-type="bibr" rid="c51">51</xref></sup>, were used to infer genomic copy numbers from scRNA-seq. In a run with inferCNV, the UMI count matrix of each tumor sample was loaded into inferCNV <italic>CreateInfercnvObject</italic> function along with cell lineage annotations. The reference (normal) cells were selected as cells annotated with T/NK, B/Plasma, myeloid, and mast cells. We maintained the proportion of epithelial cells below 20% in each tumor sample using the expression profiles of the normal lung and lymph node tissues. Inferred CNV signals were analyzed using inferCNV <italic>run</italic> function using the parameters: cutoff=0.1, denoise=TRUE, HMM=TRUE, and HMM_type=“i6”. The signals were then summarized as standard deviations (s.d.) for all windows and the correlation between the CNV in each cell and the mean of the top 5% cells <sup><xref ref-type="bibr" rid="c52">52</xref></sup>. Cancer cells showing CNV perturbation (&gt;0.03 s.d. or &gt;0.3 CNV correlation) were classified as malignant cells, otherwise as non-malignant cells. The UMI count matrix of each tumor sample was loaded into CopyKAT <italic>copykat</italic> function along with cell lineage annotations using the following parameters: ngene.chr=3, KS.cut=0.05, and norm.cell.names. Cancer cells predicted as aneuploid cells by CopyKAT were classified as malignant cells. Finally, we identified malignant cells, which are cancer cells classified as malignant cells in either inferCNV or CopyKAT.</p>
</sec>
<sec id="s4ma">
<title>Single-cell DEGs between response groups in malignant cells</title>
<p>A total of 12,975 malignant cells were used to identify DEGs in pairwise comparisons according to responder versus non-responder, PR versus PD, and PR versus SD. Differential expression levels were calculated using Seurat <italic>FindMarkers</italic> function with the Wilcoxon Rank Sum test. Genes were selected according to the following statistical thresholds: log fold change&gt;0.25, p-value&lt;0.01, adjusted p-value (bonferroni correction)&lt;0.01, and pct&gt;0.25. We reconstructed DEGs as four groups: INT.up, INT.down, UNION,up, and UNION.down, based on with the intersection (INT) and union (UNION) of up- or down-regulated genes for pairwise comparisons between responder versus non-responder, PR versus PD, and PR versus SD. INT.up and INT.down represent the intersection of up- and down-regulated genes in the responder group, respectively. UNION.up and UNION.down represent the union of up- and down-regulated genes in the responder group, respectively.</p>
</sec>
<sec id="s4n">
<title>Non-negative matrix factorization (NMF) programs of the malignant cells</title>
<p>The UMI count matrix for malignant cells was loaded into <italic>nmf</italic> function of RcppML v0.5.6 R package. A NMF model was learned with a rank of 30 using all genes. For each of the 30 NMF factors, the top-ranked 50 genes in the NMF score were defined as signatures. RECIST-enriched NMF program consisted of selected factors based on their relative sum of loadings. We aggregated and redefined gene signatures of factors included in each NMF program. The uniqueness of each NMF program for RECIST groups was evaluated as an odds ratio using <italic>fisher.test</italic> function of stats v3.6.3 R package. Annotations of NMF programs were assigned using Metascape <sup><xref ref-type="bibr" rid="c53">53</xref></sup>.</p>
</sec>
<sec id="s4o">
<title>RECIST-specific gene modules in malignant cells</title>
<p>The RECIST-specific gene modules were analyzed with a matrix factorization named scINSIGHT <sup><xref ref-type="bibr" rid="c24">24</xref></sup> using log-normalized count and 2,000 highly variable genes for each sample. For each module, we selected the 100 genes with the highest coefficients. Combinations of the top 100 genes for modules specific to each RECIST group were defined as module genes. The uniqueness of each module for RECIST groups was evaluated as an odds ratio using <italic>fisher.test</italic> function of stats v3.6.3 R package. Annotations of gene modules were assigned using Metascape <sup><xref ref-type="bibr" rid="c53">53</xref></sup>.</p>
</sec>
<sec id="s4p">
<title>Principal component signatures of the malignant cells</title>
<p>The UMI count matrix for malignant cells was log-normalized and scaled by z-transform while regressing out the effects of cell-cycle variations for PCA. A total of 2,000 variably expressed genes selected using <italic>FindVariableFeatures</italic> with selection.method=“vst” were used for PCA. PCs were calculated by Seurat <italic>RunPCA</italic> function. PC signatures were selected for 30 genes with + (pos) and – (neg) scores that highly contributed to each PC from PC1 to PC10.</p>
</sec>
<sec id="s4q">
<title>Functional category analysis</title>
<p>Functional categories representing the enriched gene expression in comparisons for responder vs. non-responder, PR vs. PD, and PR vs. SD as well as in the PCs were identified using fgsea v1.12.0 <sup><xref ref-type="bibr" rid="c54">54</xref></sup> R package with parameters: minSize=10, maxSize=600, and nperm=10000. Gene sets for Gene Ontology (GO) Biological Process were collected from the MSigDB database using msigdbr v7.1.1 R package <sup><xref ref-type="bibr" rid="c55">55</xref>,<xref ref-type="bibr" rid="c56">56</xref></sup>. The gene list was ranked by the log fold change for each comparison and feature loadings for each PC. Significant GO terms were selected after collapsing redundant terms using fgsea <italic>collapsePathways</italic> function with a statistical threshold for Benjamini-Hochberg adjusted p-value&lt;0.05.</p>
</sec>
<sec id="s4r">
<title>Multivariate overall survival analysis of tumor signatures</title>
<p>To evaluate the prognostic potential of tumor signatures, RNA sequencing data from LUAD and LUSC samples were retrieved from The Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>) <sup><xref ref-type="bibr" rid="c57">57</xref></sup>. The dataset comprised 533 primary tumors from TCGA LUAD and 502 primary tumors from TCGA LUSC. Gene expression levels were quantified as (log2 FPKM-UQ + 1), where FPKM-UQ represents the upper quartile fragments per kilobase per million mapped reads for each sample.</p>
<p>Clinical variables were first categorized, including age (below and above median age), gender (male and female), pathological stage (I/II and III/IV), distant metastasis (M0 and M1), and nodal status (N0 and Ns). Samples were then classified into high and low groups based on the upper quantile of the mean expression for each tumor signature group. Multivariate survival analysis was conducted using the <italic>analyse_multivariate</italic> function of the survivalAnalysis R package.</p>
</sec>
<sec id="s4s">
<title>Evaluation of discriminative power of identifying responders for tumor signatures and combinatorial indexes</title>
<p>Classification models of responders and non-responders for PC signatures and combinatorial indexes between tumor and/or immune cells were generated based on in-sample performance and tested by Receiver Operating Characteristic (ROC) curve. Relative numbers between the observed and expected cells (<italic>Ro/e</italic>) for each sample were obtained from the chi-square test <sup><xref ref-type="bibr" rid="c19">19</xref></sup>. To describe the separability, area under the curve (AUC) was calculated using <italic>ROC</italic> function of Epi v2.44 R package with <italic>Ro/e</italic> scores as input. Significance was calculated by Wilcoxon Rank Sum test and confirmed by adjusting with the Benjamini-Hochberg correction.</p>
</sec>
<sec id="s4t">
<title>Univariate regression analysis for ICI response</title>
<p>Univariate regression was performed using the <italic>lm</italic> function of stats v3.6.3 with <italic>Ro/e</italic> scores for each sample as input. We evaluated the relationship between the target variable ICI response, classified as responders and non-responders, and one predictor variable of immune cell types, tumor signatures, and clinical factors such as tissue origin, cancer subtype, pathological stage, and smoking status. The significance of predictor was calculated using <italic>Anova</italic> function of car v3.0-9 R package.</p>
</sec>
<sec id="s4u">
<title>Validation of PC signatures in melanoma cohorts</title>
<p>We used Riaz et al.’s <sup><xref ref-type="bibr" rid="c29">29</xref></sup> and Van Allen al.’s <sup><xref ref-type="bibr" rid="c28">28</xref></sup> RNA sequencing data from melanoma patients receiving PD-1 and CTLA-4 immune checkpoint therapy to assess expressional changes of PC signatures along RECIST. The mean expression of each PC signature in each RECIST group was calculated as the log2 normalized level.</p>
</sec>
<sec id="s4v">
<title>Data availability</title>
<p>Raw single-cell RNA sequencing data generated during the current study are available in the European Genome-phenome Archive (EGA) database (accession code EGAD00001008703), and processed data can be accessed from the NCBI Gene Expression Omnibus (GEO) database (accession code GSE205335).</p>
<p>Single-cell RNA sequencing data for LUAD patients analyzed in this study are available in the EGA database at EGAD00001005054. Bulk RNA sequencing data analyzed in this study were obtained from GEO at GSE91061 and database of Genotypes and Phenotypes (dbGap) at phs000452.v2.p1.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the Collaborative Genome Program for Fostering New Post-Genome Industry (NRF-2017M3C9A6044633 and NRF-2017M3C9A6044636), Mid-Career Researcher Program (NRF-2022R1A2C1091451), and Basic Research Laboratory Program (RS-2023-00220840) of the National Research Foundation of Korea funded by the Korea government. We also acknowledge the Basic Medical Science Facilitation Program, through the Catholic Medical Center of the Catholic University of Korea funded by the Catholic Education Foundation and the KREONET/GLORIAD service provided by KISTI (Korea Institute of Science and Technology Information).</p>
</ack>
<sec id="d1e1475" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e1670">
<label>Supplementary figures</label>
<media xlink:href="supplements/589544_file07.pdf"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reck</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer</article-title>. <source>N Engl J Med</source> <volume>375</volume>, <fpage>1823</fpage>–<lpage>1833</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1606774</pub-id> (<year>2016</year>).</mixed-citation></ref>
<ref id="c2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gandhi</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer</article-title>. <source>N Engl J Med</source> <volume>378</volume>, <fpage>2078</fpage>–<lpage>2092</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1801005</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paz-Ares</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer</article-title>. <source>N Engl J Med</source> <volume>379</volume>, <fpage>2040</fpage>–<lpage>2051</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1810865</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wakelee H</surname>, <given-names>A. N.</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Csőszi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Vynnychenko</surname> <given-names>IO</given-names></string-name>, <string-name><surname>Goloborodko</surname> <given-names>O</given-names></string-name>, <string-name><surname>Luft</surname> <given-names>A</given-names></string-name>, <string-name><given-names>Andrey</given-names> <surname>Akopov</surname></string-name>, <string-name><surname>Martinez-Marti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kenmotsu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Chella</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sugawara</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gitlitz</surname> <given-names>BJ</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>E</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>Y</given-names></string-name>, <string-name><surname>McCleland</surname> <given-names>M</given-names></string-name>, <string-name><surname>Felip</surname> <given-names>E</given-names></string-name></person-group>. <article-title>IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)</article-title>. <source>J Clin Oncol</source> <volume>39</volume>, <fpage>8500</fpage>, doi:<pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.8500</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reck</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score &gt;/= 50</article-title>. <source>J Clin Oncol</source> <volume>39</volume>, <fpage>2339</fpage>–<lpage>2349</lpage>, doi:<pub-id pub-id-type="doi">10.1200/JCO.21.00174</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fehrenbacher</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial</article-title>. <source>Lancet</source> <volume>387</volume>, <fpage>1837</fpage>–<lpage>1846</lpage>, doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(16)00587-0</pub-id> (<year>2016</year>).</mixed-citation></ref>
<ref id="c7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hellmann</surname>, <given-names>M. D.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden</article-title>. <source>N Engl J Med</source> <volume>378</volume>, <fpage>2093</fpage>–<lpage>2104</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1801946</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Litchfield</surname>, <given-names>K.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition</article-title>. <source>Cell</source> <volume>184</volume>, <fpage>596</fpage>–<lpage>614.e514,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.01.002</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kamphorst</surname>, <given-names>A. O.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>114</volume>, <fpage>4993</fpage>–<lpage>4998</lpage>, doi:<pub-id pub-id-type="doi">10.1073/pnas.1705327114</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>K. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors</article-title>. <source>Clin Cancer Res</source> <volume>25</volume>, <fpage>2144</fpage>–<lpage>2154</lpage>, doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1449</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thommen</surname>, <given-names>D. S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade</article-title>. <source>Nat Med</source> <volume>24</volume>, <fpage>994</fpage>–<lpage>1004</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41591-018-0057-z</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simon</surname>, <given-names>S.</given-names></string-name> &amp; <string-name><surname>Labarriere</surname>, <given-names>N</given-names></string-name></person-group>. <article-title>PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?</article-title> <source>Oncoimmunology</source> <volume>7</volume>, <fpage>e1364828</fpage>, doi:<pub-id pub-id-type="doi">10.1080/2162402X.2017.1364828</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Arce</given-names> <surname>Vargas</surname></string-name>, F., <etal>et al.</etal></person-group> <article-title>Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors</article-title>. <source>Immunity</source> <volume>46</volume>, <fpage>577</fpage>–<lpage>586</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2017.03.013</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krieg</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Author Correction: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy</article-title>. <source>Nat Med</source> <volume>24</volume>, <fpage>1773</fpage>–<lpage>1775</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41591-018-0094-7</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumagai</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies</article-title>. <source>Nat Immunol</source> <volume>21</volume>, <fpage>1346</fpage>–<lpage>1358</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41590-020-0769-3</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ruiz-Patino</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)</article-title>. <source>Thorac Cancer</source> <volume>11</volume>, <fpage>353</fpage>–<lpage>361</lpage>, doi:<pub-id pub-id-type="doi">10.1111/1759-7714.13272</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>, <given-names>N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma</article-title>. <source>Nat Commun</source> <volume>11</volume>, <fpage>2285</fpage>, doi:<pub-id pub-id-type="doi">10.1038/s41467-020-16164-1</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stoeckius</surname>, <given-names>M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Simultaneous epitope and transcriptome measurement in single cells</article-title>. <source>Nat Methods</source> <volume>14</volume>, <fpage>865</fpage>–<lpage>868</lpage>, doi:<pub-id pub-id-type="doi">10.1038/nmeth.4380</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>, <given-names>X.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing</article-title>. <source>Nat Med</source> <volume>24</volume>, <fpage>978</fpage>–<lpage>985</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41591-018-0045-3</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gueguen</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer</article-title>. <source>Sci Immunol</source> <volume>6</volume>, doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abd5778</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Groom</surname>, <given-names>J. R.</given-names></string-name> &amp; <string-name><surname>Luster</surname>, <given-names>A. D</given-names></string-name></person-group>. <article-title>CXCR3 in T cell function</article-title>. <source>Exp Cell Res</source> <volume>317</volume>, <fpage>620</fpage>–<lpage>631</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.yexcr.2010.12.017</pub-id> (<year>2011</year>).</mixed-citation></ref>
<ref id="c22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome</article-title>. <source>Nat Commun</source> <volume>10</volume>, <fpage>3931</fpage>, doi:<pub-id pub-id-type="doi">10.1038/s41467-019-11947-7</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer</article-title>. <source>Clin Cancer Res</source> <volume>25</volume>, <fpage>7413</fpage>–<lpage>7423</lpage>, doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0558</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Fu</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name> &amp; <string-name><surname>Li</surname>, <given-names>W. V</given-names></string-name></person-group>. <article-title>scINSIGHT for interpreting single-cell gene expression from biologically heterogeneous data</article-title>. <source>Genome Biol</source> <volume>23</volume>, <fpage>82</fpage>, doi:<pub-id pub-id-type="doi">10.1186/s13059-022-02649-3</pub-id> (<year>2022</year>).</mixed-citation></ref>
<ref id="c25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lapuente-Santana</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>van Genderen</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hilbers</surname>, <given-names>P. A. J.</given-names></string-name>, <string-name><surname>Finotello</surname>, <given-names>F.</given-names></string-name> &amp; <string-name><surname>Eduati</surname>, <given-names>F</given-names></string-name></person-group>. <article-title>Interpretable systems biomarkers predict response to immune-checkpoint inhibitors</article-title>. <source>Patterns (N Y</source><italic>)</italic> <volume>2</volume>, <fpage>100293</fpage>, doi:<pub-id pub-id-type="doi">10.1016/j.patter.2021.100293</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Betzler</surname>, <given-names>A. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>NF-kappaB and Its Role in Checkpoint Control</article-title>. <source>Int J Mol Sci</source> <volume>21</volume>, doi:<pub-id pub-id-type="doi">10.3390/ijms21113949</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fenton</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>Saleiro</surname>, <given-names>D.</given-names></string-name> &amp; <string-name><surname>Platanias</surname>, <given-names>L. C</given-names></string-name></person-group>. <article-title>Type I and II Interferons in the Anti-Tumor Immune Response</article-title>. <source>Cancers (Basel</source><italic>)</italic> <volume>13</volume>, doi:<pub-id pub-id-type="doi">10.3390/cancers13051037</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Allen</surname>, <given-names>E. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title>. <source>Science</source> <volume>350</volume>, <fpage>207</fpage>–<lpage>211</lpage>, doi:<pub-id pub-id-type="doi">10.1126/science.aad0095</pub-id> (<year>2015</year>).</mixed-citation></ref>
<ref id="c29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riaz</surname>, <given-names>N.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab</article-title>. <source>Cell</source> <volume>171</volume>, <fpage>934</fpage>–<lpage>949.e916,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.cell.2017.09.028</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lawrence</surname>, <given-names>M. S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>. <source>Nature</source> <volume>499</volume>, <fpage>214</fpage>–<lpage>218</lpage>, doi:<pub-id pub-id-type="doi">10.1038/nature12213</pub-id> (<year>2013</year>).</mixed-citation></ref>
<ref id="c31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Hu-Lieskovan</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Wargo</surname>, <given-names>J. A.</given-names></string-name> &amp; <string-name><surname>Ribas</surname>, <given-names>A.</given-names></string-name></person-group> <article-title>Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</article-title>. <source>Cell</source> <volume>168</volume>, <fpage>707</fpage>–<lpage>723</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibellini</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors</article-title>. <source>Front Immunol</source> <volume>11</volume>, <fpage>490</fpage>, doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.00490</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Pan-cancer single-cell landscape of tumor-infiltrating T cells</article-title>. <source>Science</source> <volume>374</volume>, <fpage>abe6474</fpage>, doi:<pub-id pub-id-type="doi">10.1126/science.abe6474</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koh</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Regulatory (FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer</article-title>. <source>Sci Rep</source> <volume>10</volume>, <fpage>18994</fpage>, doi:<pub-id pub-id-type="doi">10.1038/s41598-020-76130-1</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wei</surname>, <given-names>S. C.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>116</volume>, <fpage>22699</fpage>–<lpage>22709</lpage>, doi:<pub-id pub-id-type="doi">10.1073/pnas.1821218116</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ganesan</surname>, <given-names>A. P.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer</article-title>. <source>Nat Immunol</source> <volume>18</volume>, <fpage>940</fpage>–<lpage>950</lpage>, doi:<pub-id pub-id-type="doi">10.1038/ni.3775</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarke</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer</article-title>. <source>J Exp Med</source> <volume>216</volume>, <fpage>2128</fpage>–<lpage>2149</lpage>, doi:<pub-id pub-id-type="doi">10.1084/jem.20190249</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weeden</surname>, <given-names>C. E.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</article-title>. <source>Cancer Cell</source> <volume>41</volume>, <fpage>837</fpage>–<lpage>852.e836,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2023.03.019</pub-id> (<year>2023</year>).</mixed-citation></ref>
<ref id="c39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marques</surname>, <given-names>H. S.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Relationship between Th17 immune response and cancer</article-title>. <source>World J Clin Oncol</source> <volume>12</volume>, <fpage>845</fpage>–<lpage>867</lpage>, doi:<pub-id pub-id-type="doi">10.5306/wjco.v12.i10.845</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>, <given-names>S. H</given-names></string-name></person-group>. <article-title>T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer</article-title>. <source>Arch Pharm Res</source> <volume>42</volume>, <fpage>549</fpage>–<lpage>559</lpage>, doi:<pub-id pub-id-type="doi">10.1007/s12272-019-01146-9</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>, <given-names>S. H.</given-names></string-name>, <string-name><surname>Cho</surname>, <given-names>G.</given-names></string-name> &amp; <string-name><surname>Park</surname>, <given-names>S. G</given-names></string-name></person-group>. <article-title>NF-kappaB Activation in T Helper 17 Cell Differentiation</article-title>. <source>Immune Netw</source> <volume>14</volume>, <fpage>14</fpage>–<lpage>20</lpage>, doi:<pub-id pub-id-type="doi">10.4110/in.2014.14.1.14</pub-id> (<year>2014</year>).</mixed-citation></ref>
<ref id="c42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Poholek</surname>, <given-names>C. H.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen</article-title>. <source>J Exp Med</source> <volume>217</volume>, doi:<pub-id pub-id-type="doi">10.1084/jem.20191761</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jing</surname>, <given-names>B.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung</article-title>. <source>Cancer Res</source> <volume>80</volume>, <fpage>784</fpage>–<lpage>797</lpage>, doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2013</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eisenhauer</surname>, <given-names>E. A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source> <volume>45</volume>, <fpage>228</fpage>–<lpage>247</lpage>, doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id> (<year>2009</year>).</mixed-citation></ref>
<ref id="c45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kang</surname>, <given-names>H. M.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Multiplexed droplet single-cell RNA-sequencing using natural genetic variation</article-title>. <source>Nat Biotechnol</source> <volume>36</volume>, <fpage>89</fpage>–<lpage>94</lpage>, doi:<pub-id pub-id-type="doi">10.1038/nbt.4042</pub-id> (<year>2018</year>).</mixed-citation></ref>
<ref id="c46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stuart</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Comprehensive Integration of Single-Cell Data</article-title>. <source>Cell</source> <volume>177</volume>, <fpage>1888</fpage>–<lpage>1902.e1821,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wolock</surname>, <given-names>S. L.</given-names></string-name>, <string-name><surname>Lopez</surname>, <given-names>R.</given-names></string-name> &amp; <string-name><surname>Klein</surname>, <given-names>A. M</given-names></string-name></person-group>. <article-title>Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data</article-title>. <source>Cell Syst</source> <volume>8</volume>, <fpage>281</fpage>–<lpage>291.e289,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.cels.2018.11.005</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korsunsky</surname>, <given-names>I.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title>. <source>Nat Methods</source> <volume>16</volume>, <fpage>1289</fpage>–<lpage>1296</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alquicira-Hernandez</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Sathe</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ji</surname>, <given-names>H. P.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>Q.</given-names></string-name> &amp; <string-name><surname>Powell</surname>, <given-names>J. E</given-names></string-name></person-group>. <article-title>scPred: accurate supervised method for cell-type classification from single-cell RNA-seq data</article-title>. <source>Genome Biol</source> <volume>20</volume>, <fpage>264</fpage>, doi:<pub-id pub-id-type="doi">10.1186/s13059-019-1862-5</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Borcherding</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Bormann</surname>, <given-names>N. L.</given-names></string-name> &amp; <string-name><surname>Kraus</surname>, <given-names>G</given-names></string-name></person-group>. <article-title>scRepertoire: An R-based toolkit for single-cell immune receptor analysis</article-title>. <source>F1000Res</source> <volume>9</volume>, <fpage>47</fpage>, doi:<pub-id pub-id-type="doi">10.12688/f1000research.22139.2</pub-id> (<year>2020</year>).</mixed-citation></ref>
<ref id="c51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname>, <given-names>R.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes</article-title>. <source>Nat Biotechnol</source> <volume>39</volume>, <fpage>599</fpage>–<lpage>608</lpage>, doi:<pub-id pub-id-type="doi">10.1038/s41587-020-00795-2</pub-id> (<year>2021</year>).</mixed-citation></ref>
<ref id="c52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Puram</surname>, <given-names>S. V.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer</article-title>. <source>Cell</source> <volume>171</volume>, <fpage>1611</fpage>–<lpage>1624.e1624,</lpage> doi:<pub-id pub-id-type="doi">10.1016/j.cell.2017.10.044</pub-id> (<year>2017</year>).</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title>. <source>Nat Commun</source> <volume>10</volume>, <fpage>1523</fpage>, doi:<pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Korotkevich G</surname>, <given-names>S. V.</given-names></string-name></person-group>, <article-title>Sergushichev A. Fast gene set enrichment analysis</article-title>. <source>bioRxiv</source>, doi:<pub-id pub-id-type="doi">10.1101/060012</pub-id> (<year>2019</year>).</mixed-citation></ref>
<ref id="c55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Molecular signatures database (MSigDB) 3.0</article-title>. <source>Bioinformatics</source> <volume>27</volume>, <fpage>1739</fpage>–<lpage>1740</lpage>, doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id> (<year>2011</year>).</mixed-citation></ref>
<ref id="c56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>, <fpage>15545</fpage>–<lpage>15550</lpage>, doi:<pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id> (<year>2005</year>).</mixed-citation></ref>
<ref id="c57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grossman</surname>, <given-names>R. L.</given-names></string-name> <etal>et al.</etal></person-group> <article-title>Toward a Shared Vision for Cancer Genomic Data</article-title>. <source>N Engl J Med</source> <volume>375</volume>, <fpage>1109</fpage>–<lpage>1112</lpage>, doi:<pub-id pub-id-type="doi">10.1056/NEJMp1607591</pub-id> (<year>2016</year>).</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.98366.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ching-Hao</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>GlaxoSmithKline</institution>
</institution-wrap>
<city>Cambridge</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>The authors utilized single-cell RNA-seq profiling of non-small cell lung cancer (NSCLC) patient tumor samples to generate <bold>useful</bold> insights into the determinants of immune checkpoint inhibitor (ICI) responsiveness in NSCLC patients. While some of the findings add weight to the current literature, the analysis is <bold>incomplete</bold> due to the small cohort size and heterogeneous population which has limited their ability to draw statistically supported conclusion after adjusting for multiple hypothesis testing, as well as the lack of functional characterization of the findings. This study would benefit from external cohorts to both validate the findings and justify the statistical analysis undertaken.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.98366.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors study the variability of patient response of NSCLC patients on immune checkpoint inhibitors using single-cell RNA sequencing in a cohort of 26 patients and 33 samples (primary and metastatic sites), mainly focusing on 11 patients and 14 samples for association analyses, to understand the variability of patient response based on immune cell fractions and tumor cell expression patterns. The authors find immune cell fraction and clonal expansion differences, as well as tumor expression differences between responders and non-responders, partly validating previous hypotheses, and partly suggesting new markers for ICI response. Integrating immune and tumor sources of signal the authors claim to improve prediction of response markedly, albeit in a small cohort and using in-sample metrics.</p>
<p>Strengths:</p>
<p>- The problem of studying the tumor microenvironment, as well as the interplay between tumor and immune features is important and interesting and needed to explain heterogeneity of patient response and be able to predict it.</p>
<p>
- Extensive analysis of the scRNAseq data with respect to immune and tumor features on different axes of hypothesis relating to immune response and tumor immune evasion using state of the art methods.</p>
<p>
- The authors provide an interesting scRNAseq data set with well-curated cell types linked to outcomes data, which is valuable</p>
<p>
- High-quality immune cell type annotation including annotations based on additional ADT data</p>
<p>
- Integration of TCRseq to confirm subtype of T-cell annotation and clonality analysis</p>
<p>
- Interesting analysis of cell programs/states of the (predicted) tumor cells and characterization thereof</p>
<p>Weaknesses:</p>
<p>- Generally a very heterogeneous and small cohort where adjustments for confounding is hard. Additionally, there are many tests for association with outcome, where necessary multiple testing adjustments negate signal and confirmation bias likely, so biological take-aways have to be questioned.</p>
<p>
- The authors claim a very high &quot;accuracy&quot; performance, however given the small cohort and possible overfitting due to in-sample ROC the generalization of this to other cohorts is questionable.</p>
<p>
- Due to the small cohort with a lot of variability, more external validation is needed to be convincingly reproducible, especially when talking about AUC/accuracy of a predictor.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.98366.2.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors have utilised deep profiling methods to generate deeper insights into the features of the TME that drive responsiveness to PD-1 therapy in NSCLC.</p>
<p>Strengths:</p>
<p>The main strengths of this work lie in the methodology of integrating single cell sequencing, genetic data and TCRseq data to generate hypotheses regarding determinants of IO responsiveness.</p>
<p>Some of the findings in this study are not surprising and well precedented eg. association of Treg, STAT3 and NFkB with ICI resistance and CD8+ activation in ICI responders and thus act as an additional dataset to add weight to this prior body of evidence. Whilst the role of Th17 in PD-1 resistance has been previously reported (eg. Cancer Immunol Immunother 2023 Apr;72(4):1047-1058, Cancer Immunol Immunother 2024 Feb 13;73(3):47, Nat Commun. 2021; 12: 2606 ) these studies have used non-clinical models or peripheral blood readouts. Here the authors have supplemented current knowledge by characterization of the TME of the tumor itself.</p>
<p>Weaknesses:</p>
<p>Unfortunately, the study is hampered by the small sample size and heterogeneous population and whilst the authors have attempted to bring in an additional dataset to demonstrate robustness of their approach, the small sample size has limited their ability to draw statistically supported conclusions. There is also limited validation of signatures/methods in independent cohorts and no functional characterisation of the findings. Because of these factors, this work (as it stands) does have value to the field but will likely have a relatively low overall impact.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.98366.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Nayoung</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Sehhoon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jo</surname>
<given-names>Areum</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eum</surname>
<given-names>Hye Hyeon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Hong Kwan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Kyungjong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Jong Ho</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ku</surname>
<given-names>Bo Mi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jung</surname>
<given-names>Hyun Ae</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Jong-Mu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Se-Hoon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahn</surname>
<given-names>Jin Seok</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jung-Il</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choi</surname>
<given-names>Jung Won</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeong</surname>
<given-names>Dasom</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Na</surname>
<given-names>Minsu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Huiram</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Jeong Yeon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choi</surname>
<given-names>Jung Kyoon</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Hae-Ock</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5123-0322</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Ahn</surname>
<given-names>Myung-Ju</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p>Summary:</p>
<p>The authors study the variability of patient response of NSCLC patients on immune checkpoint inhibitors using single-cell RNA sequencing in a cohort of 26 patients and 33 samples (primary and metastatic sites), mainly focusing on 11 patients and 14 samples for association analyses, to understand the variability of patient response based on immune cell fractions and tumor cell expression patterns. The authors find immune cell fraction, clonal expansion differences, and tumor expression differences between responders and non-responders. Integrating immune and tumor sources of signal the authors claim to improve prediction of response markedly, albeit in a small cohort.</p>
<p>Strengths:</p>
<p>The problem of studying the tumor microenvironment, as well as the interplay between tumor and immune features is important and interesting and needed to explain the heterogeneity of patient response and be able to predict it.</p>
<p>Extensive analysis of the scRNAseq data with respect to immune and tumor features on different axes of hypothesis relating to immune response and tumor immune evasion using state-of-the-art methods.</p>
<p>The authors provide an interesting scRNAseq data set linked to outcomes data.</p>
<p>Integration of TCRseq to confirm subtype of T-cell annotation and clonality analysis.</p>
<p>Interesting analysis of cell programs/states of the (predicted) tumor cells and characterization thereof.</p>
<p>Weaknesses:</p>
<p>Generally, a very heterogeneous and small cohort where adjustments for confounding are hard. Additionally, there are many tests for association with outcome, where necessary multiple testing adjustments would negate signal and confirmation bias likely, so biological takeaways have to be questioned.</p>
</disp-quote>
<p>Thank you for your comment. We made multiple testing adjustments as suggested in “Recommendations for Authors.”</p>
<disp-quote content-type="editor-comment">
<p>RNAseq is heavily influenced by the tissue of origin (both cell type and expression), so the association with the outcome can be confounded. The authors try to argue that lymph node T-cell and NK content are similar, but a quantitative test on that would be helpful.</p>
</disp-quote>
<p>Following the reviewer’s suggestion, we performed principal component analysis (PCA) to assess the influence of tissue of origin on immune and stromal cell populations. In the revised Figure S1g, we quantified the similarity using Euclidean distances of centroids between sample groups based on their tissue of origin in the PC1 and PC3 plot.</p>
<disp-quote content-type="editor-comment">
<p>The authors claim a very high &quot;accuracy&quot; performance, however, given the small cohort and lack of information on the exact evaluation it is not clear if this just amounts to overfitting the data.</p>
</disp-quote>
<p>We acknowledge the concern about the high “accuracy” potentially indicating overfitting. To address this, we revised the manuscript to clarify the use of 'accuracy,' 'AUC,' and 'performance' with clearer expressions in the following sections: Abstract (Line 57), Results (Line 264), Discussion (Lines 320-321), Methods (Lines 546-547), Legends for Figure 5c and Figure S8b.</p>
<disp-quote content-type="editor-comment">
<p>Especially for tumor cell program/state analysis the specificity to the setting of ICIs is not clear and could be prognostic.</p>
</disp-quote>
<p>Thank you for your comments. As outlined in the ‘Table 2 in the revised manuscript’, we conducted a multivariate survival analysis of tumor signature candidates using the TCGA lung adenocarcinoma (LUAD, n = 533) and squamous cell carcinoma (LUSC, n = 502) cohorts to evaluate their prognostic potential. No tumor cell programs or states were found to be associated with overall survival in either LUAD or LUSC. We added descriptions related to Table 2 in the Results (Lines 249-251) and Methods (Lines 530-542) section.</p>
<disp-quote content-type="editor-comment">
<p>Due to the small cohort with a lot of variability, more external validation is needed to be convincingly reproducible, especially when talking about AUC/accuracy of a predictor.</p>
</disp-quote>
<p>Expanding the cohort size was difficult due to limited resources. We recognize the challenges posed by the small and heterogeneous cohort. We have acknowledged these limitations and applied statistical corrections to address them.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>Summary:</p>
<p>The authors have utilised deep profiling methods to generate deeper insights into the features of the TME that drive responsiveness to PD-1 therapy in NSCLC.</p>
<p>Strengths:</p>
<p>The main strengths of this work lie in the methodology of integrating single-cell sequencing, genetic data, and TCRseq data to generate hypotheses regarding determinants of IO responsiveness.</p>
<p>Some of the findings in this study are not surprising and well precedented eg. association of Treg, STAT3, and NFkB with ICI resistance and CD8+ activation in ICI responders and thus act as an additional dataset to add weight to this prior body of evidence. Whilst the role of Th17 in PD-1 resistance has been previously reported (eg. Cancer Immunol Immunother 2023 Apr;72(4):1047-1058, Cancer Immunol Immunother 2024 Feb 13;73(3):47, Nat Commun. 2021; 12: 2606 ) these studies have used non-clinical models or peripheral blood readouts. Here the authors have supplemented current knowledge by characterization of the TME of the tumor itself.</p>
<p>Weaknesses:</p>
<p>Unfortunately, the study is hampered by the small sample size and heterogeneous population and whilst the authors have attempted to bring in an additional dataset to demonstrate the robustness of their approach, the small sample size has limited their ability to draw statistically supported conclusions. There is also limited validation of signatures/methods in independent cohorts, no functional characterization of the findings, and the discussion section does not include discussion around the relevance/interpretation of key findings that were highlighted in the abstract (eg. role of Th17, TRM, STAT3, and NFKb). Because of these factors, this work (as it stands) does have value to the field but will likely have a relatively low overall impact.</p>
</disp-quote>
<p>We acknowledge the challenges posed by the small and heterogeneous cohort. To address this, we tempered our claims related to accuracy by applying statistical testing corrections. We also appreciate the feedback on functional characterization and have expanded the discussion in the revised manuscript to include an overview of specific cell populations and genes.</p>
<disp-quote content-type="editor-comment">
<p>Related to the absence of discussion around prior TRM findings, the association between TRM involvement in response to IO therapy in this manuscript is counter to what has been previously demonstrated (Cell Rep Med. 2020;1(7):100127, Nat Immunol. 2017;18(8):940-950., J Immunol. 2015;194(7):3475-3486.). However, it should be noted that the authors in this manuscript chose to employ alternative markers of TRM characterisation when defining their clusters and this could indicate a potential rationale for differences in these findings. TRM population is generally characterised through the inclusion of the classical TRM markers CD69 (tissue retention marker) and CD103 (TCR experienced integrin that supports epithelial adhesion), which are both absent from the TRM definition in this study. Additional markers often used are CD44, CXCR6, and CD49a, of which only CXCR6 has been included by the authors. Conversely, the majority of markers used by the authors in the cell type clustering are not specific to TRM (eg. CD6, which is included in the TRM cluster but is expressed at its lowest in cluster 3 which the authors have highlighted as the CD8+ TRM population). Therefore, whilst there is an interesting finding of this particular cell cluster being associated with resistance to ICI, its annotation as a TRM cluster should be interpreted with caution.</p>
</disp-quote>
<p>Single-cell RNA sequencing (scRNA-seq) can sometimes fail to detect the expression of classical cell type markers due to incomplete capture of a cell’s transcriptome. To determine cell identity, we utilized cell type markers established in previous scRNA-seq studies. In response to your comments, we have added the expression levels of classical TRM markers, including CD69, CD103 (ITGAE), CD44, CXCR6, and CD49a (ITGA1), in the revised Figure 2c. Although these markers were not exclusively expressed in TRM clusters, TRM clusters exhibited relatively high levels of these genes while lacking other clusters’ specific marker genes.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p>
<p>General suggestions:</p>
<p>When analyzing the association of cell type proportions with outcomes, some adjustment for multiple testing should be considered (either sampling-based, e.g. permutation test, or adjustment based on assumptions of independence of tests, e.g. Bonferroni).</p>
</disp-quote>
<p>Thank you for your comments. As suggested, we calculated the adjusted p-value using the False Discovery Rate for the association of cell type proportions with outcomes in Figure 3a. The heatmap in Reviewer's ONLY Figure 1, using the adjusted p-value consistently showed the expected grouping of cell types and outcomes. However, the significance did not meet the conventional statistical cutoff criteria. We acknowledge this limitation, which results from statistical testing based on ratio values.</p>
<fig id="sa3fig1">
<label>Author response image 1.</label>
<caption>
<title>Heat map with unsupervised hierarchical clustering of proportional changes in cell subtypes within total immune cells.</title>
<p>Proportional changes were compared across multiple ICI response groups. The color represents the adjusted -log (p-value) calculated using the False Discovery Rate.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-98366-sa3-fig1.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>A formal test of clonotype differences (normalized to cell type fraction) would be great as the shown plot 2e could be confounded by cell number and type differences between responders and non-responders.</p>
</disp-quote>
<p>Thank you for your suggestion. We have revised Figure 2e to display the relative clonotype differences versus CD4+ and CD8+ T cell fractions in each sample. The relative clone size of each cell was calculated by dividing the size of each clone by the total number of CD4+ or CD8+ T cells, respectively.</p>
<disp-quote content-type="editor-comment">
<p>It could be made a bit more clear when the core group of patients was used (only when associating with outcomes?) and when all other patients were used as well (only cell type annotation?).</p>
</disp-quote>
<p>As the reviewer correctly noted, we performed scRNA-seq analysis on all specimens, but only the core group of patients was used for the comparative analysis between the responder and non-responder groups. This information has been detailed in the manuscript (Lines 103-105).</p>
<disp-quote content-type="editor-comment">
<p>For immune cells, it would be interesting to look at expression patterns (NMF, scINSIGHT) as well, not just immune cell fractions and expansion.</p>
</disp-quote>
<p>In contrast to tumor signatures, immune cell programs are more directly tied to their functional characteristics. Therefore, we focused on annotating immune cells based on their functional properties and conducted comparative analyses between responders and non-responders.</p>
<disp-quote content-type="editor-comment">
<p>Multiple testing is necessary for the univariate association analysis. Some adjustments for confounders in a multivariate model (despite the size) could be informative.</p>
</disp-quote>
<p>As shown in ‘Reviewer's ONLY Table 1’, we conducted a multivariate regression analysis of immune and tumor signatures for ICI response, adjusting for clinical variables such as tissue origin, cancer subtype, pathological stage, and smoking status. However, the results were not significant, likely due to the heterogeneity and small size of the cohort.</p>
<table-wrap id="sa3table1">
<label>Author response table 1.</label>
<caption>
<title>P-values from univariate and multivariate regression analysis of immune and tumor signatures for ICI response.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-98366-sa3-table1.jpg" mimetype="image"/>
</table-wrap>
<disp-quote content-type="editor-comment">
<p>It is not clear from the manuscript how &quot;accuracy&quot; is measured. The terms &quot;accuracy&quot; and &quot;AUC&quot;, as well as &quot;performance&quot; are used interchangeably, a section in the methods with the precise definition is needed.</p>
</disp-quote>
<p>We have revised the manuscript to clarify the terms 'accuracy,' 'AUC,' and 'performance' by using clearer expressions in the following sections: Abstract (Line 57), Results (Line 264), Discussion (Lines 320-321), Methods (Lines 546-547), Legends for Figure 5c and Figure S8b.</p>
<disp-quote content-type="editor-comment">
<p>Furthermore, it has to be clear if this is in-sample performance or if there was some train/test split or cross-validation used. Given the small cohort size and wealth of features finding some combination of predictors that could overfit on responders/non-responders would not be surprising.</p>
</disp-quote>
<p>As the reviewer has noted, we acknowledge the statistical limitations due to the small cohort size. We have revised the sentence on Lines 545-547 “Classification models of responders and non-responders for PC signatures and combinatorial indexes between tumor and/or immune cells were generated based on in-sample performance…”.</p>
<disp-quote content-type="editor-comment">
<p>Suggestions to improve readability:</p>
<p>Line 84: The sentence should be reformulated to improve understanding.</p>
</disp-quote>
<p>We have revised sentences in lines 81-93.</p>
<disp-quote content-type="editor-comment">
<p>Line 86: missing a &quot;the&quot;.</p>
</disp-quote>
<p>We have revised the sentences in lines 81-93.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>&quot;Tumor-infiltrating PD-1 positive T cells have higher capacity of tumor recognition than PD-1 negative T cells&quot; Please look to rephrase this sentence as this is not entirely accurate: PD-1 is upregulated in tumor-experienced T cells as a consequence of antigen recognition ie those cells that recognise tumor will increase PD-1, whereas the sentence as it's currently written indicates that PD1+ cells have an intrinsically increased capacity to kill tumors, which is incorrect.</p>
</disp-quote>
<p>We have revised the sentence “Tumor-infiltrating PD-1 positive T cells have higher capacity of tumor recognition than PD-1 negative T cells” in lines 86-88 as “More specifically, PD-1 expression is upregulated upon antigen recognition (PMID29296515), indicating that certain T cells in the tumor microenvironment are actively engaged as tumor-specific T cells.” in the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Cancer subtype abbreviations (eg. SQ, ADC, NUT) are used in figures in the main article and so should be defined in the main text (they are currently only explained in the legend for the supplementary table).</p>
</disp-quote>
<p>As per the reviewer’s suggestion, the manuscript has been revised to include definitions of cancer type abbreviations in lines 108-110.</p>
<disp-quote content-type="editor-comment">
<p>Figure S1d-f does not appear to corroborate the statement that &quot;Although there were differences in tissue-specific resident populations, we found that the immune cell profiles, especially T/NK cells of mLN were similar to those of primary tumor tissues indicating the activation of immune responses were 118 consistently observed at metastatic sites (Figure S1d-f).&quot; The diagrams are complex (please explain all abbreviations) and it is not clear how the authors have come to this conclusion. Additionally, cell quantity does not indicate that the 'activation of immune responses' is consistently observed at metastatic sites as these cells could be dysfunctional/bystander.</p>
</disp-quote>
<p>In the revision, we have quantified the diagrams (Figure S1f) to more clearly highlight the differences in tissue-specific resident populations. We performed principal component analysis (PCA) to evaluate the impact of tissue origin on immune and stromal cell populations. In the revised Figure S1g, we illustrated the quantitative similarity between sample groups using Euclidean distances in the PC plot based on their tissue of origin. Additionally, the legends for Figures S1d and S1e have been updated to include definitions for all abbreviations.</p>
<p>We agree with the reviewer's comment that cell quantity alone may not fully reflect activation of antigen-specific immune responses, even though we annotated the functional T cell subtypes. To better focus on the comparisons of cellular profiles between metastatic sites (mLN) and primary tumors (tLung and tL/B), we removed the sentence “…indicating the activation of immune responses were consistently observed at metastatic sites (Fig. S1d-f).” from the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>In Figure 2c, classical markers for TRM (CD103, CD69) should be included in the description for the definition of the TRM clusters, or their exclusion appropriately explained. The findings regarding the negative correlation between follicular B cells and ICI response are surprising. Figure S3, the cluster identified as Follicular B cells contains MS4A1 (CD20) and HLA-DRA. Classical markers are CD20 (pan-B cell), CD21 (CR2), CD23, and IgD/IgM (double positive), and as such it is not clear if the authors have appropriately annotated this cluster as representing follicular B cells. These classical markers should be included in the interpretation of the cell clustering or their exclusion appropriately explained.</p>
</disp-quote>
<p>We appreciate your comments. In response, we have added the expression levels of classical TRM markers such as CD69, CD103 (ITGAE), CD44, CXCR6, and CD49a (ITGA1), in the revised Figure 2c. Additionally, we revised the dot plot showing the mean expression of marker genes in each cell cluster for B/Plasma cells (revised Figure S3b) by incorporating classical markers for Follicular B cells, such as CD21 (CR2), CD23 (FCER2), IgD (IGHD), IgM (IGHM).</p>
<disp-quote content-type="editor-comment">
<p>Figure 2f is rather confusing for the reader. I would recommend changing to an alternative plot that shows logP and response in a different way. If keeping to this plot type please clarify why plotting response vs PD, and whether the lower left quadrant indicates patients with progressive disease and the top right indicates responders as the interpretation is not clear currently.</p>
</disp-quote>
<p>Thank you for your feedback. To address the concerns raised, we have updated the figure legend for Figure 2f to clarify the interpretation of the quadrants: “The lower left quadrant shows cell types overrepresented in the poor responder groups, while the upper right quadrant indicates cell types overrepresented in the better responder groups”. This clarification aims to help readers understand that the lower left quadrant reflects cell types associated with worse treatment outcomes, while the upper right quadrant reflects cell types associated with improved therapeutic responses.</p>
<disp-quote content-type="editor-comment">
<p>The terms &quot;PC7.neg, INT.down, and UNION.down&quot; are included in the results with no explanation to the reader of what they are or how to interpret them. The methods description &quot;We constructed DEGs with 470 intersections (INT) and union (UNION) of up- or down-regulated genes for comparisons&quot; does not sufficiently describe how they were generated/calculated and, therefore, this is difficult for the reader to interpret in the final results section. Please add an additional explanation for the reader in the final section of the results/Figure 5 and in the methods.</p>
</disp-quote>
<p>Following the reviewer’s suggestion, we added additional explanation in the Results section (lines 258-261): “PC7.neg denotes genes negatively correlated with PC7, a principal component extracted from PCA that distinguishes tumor cells in poor response groups. INT.down and UNION.down represent the intersection and union of down-regulated genes in the responder group, respectively.”. We also explained the details in the Methods section (lines 489-495): “We reconstructed DEGs as four groups: INT.up, INT.down, UNION,up, and UNION.down, based on with the intersection (INT) and union (UNION) of up- or down-regulated genes for pairwise comparisons between responder versus non-responder, PR versus PD, and PR versus SD. INT.up and INT.down represent the intersection of up- and down-regulated genes in the responder group, respectively. UNION.up and UNION.down represent the union of up- and down-regulated genes in the responder group, respectively.”</p>
<disp-quote content-type="editor-comment">
<p>The TRM and Th17+ T cell populations are highlighted in the abstract as being related to ICI resistance, but these populations of cells are not even mentioned in the discussion. Likewise, STAT3 and NFkb pathways are also highlighted in the abstract but absent in the discussion section. Please discuss the relevance of these findings, particularly given the prior studies demonstrating the opposite impact of TRM populations in NSCLC.</p>
</disp-quote>
<p>We have expanded the discussion in the revised manuscript (Lines 295-313) to address the roles of TRM and Th17+ T cell, as well as the STAT3 and NF-κB pathways, in association with ICI resistance in NSCLC.</p>
<p>“The identification of an abundance of CD4+ TRM cells as a negative predictor of ICI response is an unexpected finding, considering that higher frequencies of TRM cells in lung tumor tissues are generally associated with better clinical outcomes in NSCLC (PMID28628092). This is largely due to their role in sustaining high densities of tumor-infiltrating lymphocytes and promoting anti-tumor responses. Additionally, previous studies have demonstrated that TRM cell subsets coexpressing PD-1 and TIM-3 are relatively enriched in patients who respond to PD-1 inhibitors (PMID31227543). However, recent findings suggest that pre-existing TRM-like cells in lung cancer may promote immune evasion mechanisms, contributing to resistance to immune checkpoint blockade therapies (PMID37086716). These observations suggest that the roles of TRM subsets in tumor immunity are highly context-dependent.</p>
<p>Similarly, CD4+ TH17 cells, which were overrepresented in the non-responder groups, exhibit context-dependent roles in tumor immunity and may be associated with both unfavorable and favorable outcomes (PMID34733609; PMID30941641). In exploring tumor cell signatures linked to ICI response, non-responder attributes were regulated by STAT3 and NFKB1. The STAT3 and NF-κB pathways are crucial for Th17 cell differentiation and T cell activation (PMID24605076; PMID32697822). Notably, STAT3 activation in lung cancer orchestrates immunosuppressive characteristics by inhibiting T-cell mediated cytotoxicity (PMID31848193). The combined influence of the Th17/STAT3 axis and TRM cell activity in predicting ICI response underscores the complexity of these pathways and suggests that their roles in tumor immunity and therapy response warrants further investigation.”</p>
</body>
</sub-article>
</article>